DALLAS, Sept. 10 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC
Bulletin Board: ACCP), provided an update today on the Company's clinical
development plan for ProLindac, a novel DACH platinum drug that has shown to
be active in many solid tumor types in human clinical studies. Access'
clinical development team recently met with its partners Aosaikang Medicinal
Group (ASK) in Nanjing, China and JCOM, Ltd. ("JCOM") in Seoul, Korea,
together with key opinion leaders in oncology indications to discuss the
protocols for the three planned ProLindac combination studies. Access and its
partners are finalizing development plans and protocols for clinical trials
strategically designed to examine ProLindac in combination with gemcitabine
and/or taxol in hepatocellular carcinoma (a form of liver cancer), pancreatic
cancer and recurrent ovarian cancer.
